Biosimilar Patent Settlements: What Terms May Spur Antitrust Actions?

AbbVie's Humira settlements suggest issues that FTC will be scrutinizing, such as biosimilar entry date, royalty payments, and acceleration clauses.

Antitrust  law gavel

One of the questions hovering around the US biosimilars space is what kind of patent settlements will prompt antitrust enforcement actions by the Federal Trade Commission and others. While the answer remains to be seen, stakeholders are preparing for government scrutiny.

A panel of two lawyers and an economist discussed the antitrust landscape for biosimilars during an Oct. 4 webinar hosted...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Biosimilars

More from Biosimilars & Generics